By Fineline Cube 
Merck, Sharp & Dohme (MSD, NYSE: MRK) this week announced the first patient dosing in the IDeate-Prostate01 Phase III trial. The trial is evaluating the investigational drug ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed during or after androgen receptor pathway inhibitor therapy.
Drug Profile
Ifinatamab deruxtecan is a potential first-in-class B7-H3-targeted DXd antibody-drug conjugate (ADC) discovered by Japan’s Daiichi Sankyo (Tokyo: 4568). It is co-developed by MSD and Daiichi Sankyo.
Previous Designations
The drug previously received Orphan Drug Designations (ODDs) from the US FDA, European Commission, Japan MHLW, and Taiwan FDA for the treatment of small cell lung cancer.-Fineline Info & Tech